RENASYS™ EDGE Negative Pressure Wound Therapy System wins Red Dot Award for Design
16 Ottobre 2024 - 3:00PM
UK Regulatory
RENASYS™ EDGE Negative Pressure Wound Therapy System wins Red Dot
Award for Design
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology
company, is proud to announce that its RENASYS EDGE Negative
Pressure Wound Therapy (NPWT) System has won the Red Dot Award for
Design Concept 2024 in the Medical Devices and Technology Category,
recognizing its intuitive pairing of NPWT housed in a
patient-friendly design.
The Red Dot Awards celebrate new innovations and groundbreaking
designs, with recipients ranging from concepts and prototypes to
full Ready For Market products.
Launched in 2024, the RENASYS EDGE NPWT System is a
patient-centric option for treating chronic wounds. The system is
lightweight and compact allowing it to be easily carried or
worn,1 it features a discreet canister, and
operates quietly so as not to draw attention or disturb the
patients’ daily activities.1
It is estimated that the annual financial burden of chronic
wounds in the US is $33 billion,2 and affecting
some 8.2 million people.*3 The RENASYS EDGE System
is designed for patients suffering from these wounds and living at
home. Chronic wounds, including ulcers, have a huge impact on a
patient’s life beyond just the pain and discomfort, with 68% often
becoming self-conscious of their wound and many becoming
isolated.4 The need to carry a bulky, noisy medical
device that draws attention to their condition only increases this
discomfort.
Smith+Nephew’s PICO◊ 14 NPWT System also won a Red
Dot Award for Design Concept in 2021 for its lightweight, discreet
and portable design which provides patients with high
mobility.5-7
-ends-
Enquiries
Media
Dave Snyder |
+1
978-749-1440 |
Smith+Nephew |
dave.snyder@smith-nephew.com |
|
|
* based on Medicare beneficiaries
References
- Smith+Nephew 2022. Internal Report. EO.AWM.PCS270.003.v1.
- Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M,
Parsons NB. Burden of diabetic foot ulcers for Medicare and private
insurers. Diabetes Care. 2014 Mar;37(3):651-8. Numbers are rounded
where appropriate.
- Sen CK. Human wounds and its burden: An updated compendium of
estimates. Advances in Wound Care, 2019; 8(2):39-48
- Phillips T, StantonB, Provan A, Lew R. A study of the impact of
leg ulcers on quality of life: financial, social, and psychologic
implications. J Am Acad Dermatol. 1994;31(1):49–53
- Gilchrist B, et al. Paper presented at: SAWC; 2020;
Virtual.
- Smith+Nephew 2020. Internal Report. 2001002.
- Smith+Nephew 2018. Internal Report. DS.18.066.R.
For detailed product information, including indications for
use, contraindications, precautions and warnings, please consult
the product’s applicable Instructions for Use (IFU) prior to
use.
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused on
the repair, regeneration and replacement of soft and hard tissue.
We exist to restore people's bodies and their self-belief by using
technology to take the limits off living. We call this purpose
'Life Unlimited'. Our 18,000 employees deliver this mission every
day, making a difference to patients' lives through the excellence
of our product portfolio, and the invention and application of new
technologies across our three global business units of
Orthopaedics, Sports Medicine & ENT and Advanced Wound
Management.
Founded in Hull, UK, in 1856, we now operate in more than
100 countries, and generated annual sales of $5.5
billion in 2023. Smith+Nephew is a constituent of the FTSE100
(LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used
to refer to Smith & Nephew plc and its consolidated
subsidiaries, unless the context requires otherwise.
For more information about Smith+Nephew,
please visit www.smith-nephew.com and follow us
on X, LinkedIn, Instagram or Facebook.
Forward-looking Statements
This document may contain forward-looking statements that
may or may not prove accurate. For example, statements regarding
expected revenue growth and trading profit margins, market trends
and our product pipeline are forward-looking statements. Phrases
such as "aim", "plan", "intend", "anticipate", "well-placed",
"believe", "estimate", "expect", "target", "consider" and similar
expressions are generally intended to identify forward-looking
statements. Forward-looking statements involve known and unknown
risks, uncertainties and other important factors that could cause
actual results to differ materially from what is expressed or
implied by the statements. For Smith+Nephew, these factors include:
conflicts in Europe and the Middle East, economic and financial
conditions in the markets we serve, especially those affecting
healthcare providers, payers and customers; price levels for
established and innovative medical devices; developments in medical
technology; regulatory approvals, reimbursement decisions or other
government actions; product defects or recalls or other problems
with quality management systems or failure to comply with related
regulations; litigation relating to patent or other claims; legal
and financial compliance risks and related investigative, remedial
or enforcement actions; disruption to our supply chain or
operations or those of our suppliers; competition for qualified
personnel; strategic actions, including acquisitions and disposals,
our success in performing due diligence, valuing and integrating
acquired businesses; disruption that may result from transactions
or other changes we make in our business plans or organisation to
adapt to market developments; relationships with healthcare
professionals; reliance on information technology and
cybersecurity; disruptions due to natural disasters, weather and
climate change related events; changes in customer and other
stakeholder sustainability expectations; changes in taxation
regulations; effects of foreign exchange volatility; and numerous
other matters that affect us or our markets, including those of a
political, economic, business, competitive or reputational nature.
Please refer to the documents that Smith+Nephew has filed with the
U.S. Securities and Exchange Commission under the U.S. Securities
Exchange Act of 1934, as amended, including Smith+Nephew's most
recent annual report on Form 20-F, which is available on the SEC’s
website at www. sec.gov, for a discussion of certain of these
factors. Any forward-looking statement is based on information
available to Smith+Nephew as of the date of the statement. All
written or oral forward-looking statements attributable to
Smith+Nephew are qualified by this caution. Smith+Nephew does not
undertake any obligation to update or revise any forward-looking
statement to reflect any change in circumstances or in
Smith+Nephew's expectations.
◊ Trademark of Smith+Nephew. Certain
marks registered in US Patent and Trademark Office.
Grafico Azioni Smith & Nephew (LSE:SN.)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Smith & Nephew (LSE:SN.)
Storico
Da Dic 2023 a Dic 2024